Jingjing Jiang
Vice President, Translational Research Revolution Medicines
Seminars
Wednesday 9th September 2026
Targeting Oncogenic RAS With Tri-Complex RAS(ON) Inhibitors
5:00 pm
- New Class of Mutant-Targeted Catalytic RAS(ON) Inhibitors
- Exploring strategic combination approaches to amplify efficacy and expand therapeutic reach, building on emerging insights across RAS driven tumor biology
- Showcasing a major year of clinical progress in the field
Tuesday 8th September 2026
Panel Discussion: How Do We Build Combination Strategies That Work Across KRAS Alleles, Co Mutations, & Tumor Types?
1:00 pm
- How do KRAS alleles, co‑mutations, and tumor lineage reshape dependency and escape, and what does that mean for choosing the right combination backbone?
- Which combinations have true cross‑context potential, and which are only effective in specific molecular or tumor‑type settings?
- How should we prioritise combinations that balance biological rationale, toxicity constraints, and real‑world feasibility across heterogeneous patient populations?
